Treatment Response Imaging in Prostate Cancer

被引：0
作者：
Swiha, Mina [1 ,2 ]
Gafita, Andrei [3 ]
Nguyen, Andrew [1 ,4 ]
Emmett, Louise [1 ,4 ,5 ]
机构：
[1] St Vincents Hosp, Dept Theranost & Nucl Med, Sydney, Australia
[2] Univ Western Ontario, Dept Med Imaging, Nucl Med Div, London, ON, Canada
[3] Johns Hopkins Med, Russell H Morgan Dept Radiol & Radiol Sci, Nucl Med & Mol Imaging Div, Baltimore, MD USA
[4] Univ New South Wales, St Vincents Clin Sch, Sydney, Australia
[5] Garvan Inst Med Res, Sydney, Australia
来源：
PET CLINICS | 2024年 / 19卷 / 03期
关键词：
Prostate cancer; PSMA-PET; PSMA-SPECT; 177Lu-PSMA; Treatment response; PSMA-PET; RADIOLIGAND THERAPY; OPEN-LABEL; CRITERIA; MITOXANTRONE; CABAZITAXEL; TOMOGRAPHY; PREDNISONE; RECIST;
D O I：
10.1016/j.cpet.2024.03.009
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Posttherapy imaging is a crucial tool for response assessment to both local and systemic therapies in early stage and late -stage PCa, with conventional imaging (diagnostic CT and bone scan) currently remaining standard of care. PSMA PET/ CT, an innovative molecular imaging tool, has shown potential in response assessment in PCa, but more research is required to validate it for clinical use. PSMA SPECT/CT is a potential costeffective alternative to PSMA PET/CT in assessment of response to PSMA-targeted radionuclide therapy that also warrants further evaluation. 18 F- FDG-PET/CT have a complementary role in nonPSMA-avid disease.
引用
收藏
页码：417 / 430
页数：14
相关论文
共 51 条
  • [1] Increased PSMA Expression in 177Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide A Potential Game-Changer
    Aggarwal, Piyush
    Kaur, Komalpreet
    Sood, Ashwani
    Periasamy, Kannan
    Nagi, Shreya
    Mittal, Bhagwant Rai
    [J]. CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 411 - 413
  • [2] PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature
    Alongi, Pierpaolo
    Laudicella, Riccardo
    Lanzafame, Helena
    Farolfi, Andrea
    Mapelli, Paola
    Picchio, Maria
    Burger, Irene A.
    Iagaru, Andrei
    Minutoli, Fabio
    Evangelista, Laura
    [J]. CANCERS, 2022, 14 (07)
  • [3] Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer
    Anton, Angelyn
    Kamel Hasan, Olfat
    Ballok, Zita
    Bowden, Patrick
    Costello, Anthony J.
    Harewood, Laurence
    Corcoran, Niall M.
    Dundee, Phil
    Peters, Justin S.
    Lawrentschuk, Nathan
    Troy, Andrew
    Webb, David
    Chan, Yee
    See, Andrew
    Siva, Shankar
    Murphy, Declan
    Hofman, Michael S.
    Tran, Ben
    [J]. BJU INTERNATIONAL, 2020, 126 (04) : 433 - 435
  • [4] Baumann R, 2018, STRAHLENTHER ONKOL, V194, P318, DOI 10.1007/s00066-017-1239-1
  • [5] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial
    Buteau, James P.
    Martin, Andrew J.
    Emmett, Louise
    Iravani, Amir
    Sandhu, Shahneen
    Joshua, Anthony M.
    Francis, Roslyn J.
    Zhang, Alison Y.
    Scott, Andrew M.
    Lee, Sze-Ting
    Azad, Arun A.
    McJannett, Margaret M.
    Stockler, Martin R.
    Williams, Scott G.
    Davis, Ian
    Hofman, Michael S.
    [J]. LANCET ONCOLOGY, 2022, 23 (11) : 1389 - 1397
  • [6] Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
    Calais, Jeremie
    Fendler, Wolfgang P.
    Herrmann, Ken
    Eiber, Matthias
    Ceci, Francesco
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 789 - 794
  • [7] Caromile LA, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1321168
  • [8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
  • [9] 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
    de Jong, Anouk C.
    Segbers, Marcel
    Ling, Sui Wai
    Graven, Laura H.
    Mehra, Niven
    Hamberg, Paul
    Brabander, Tessa
    de Wit, Ronald
    van der Veldt, Astrid A. M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (10) : 1556 - 1562
  • [10] Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice
    Denis, Chloe S.
    Cousin, Francois
    De Laere, Bram
    Hustinx, Roland
    Sautois, Brieuc R.
    Withofs, Nadia
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) : 1815 - 1821
123456